Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™
In the study presented at ILC, PiZ mice were treated with ARC-AAT for 33 weeks. Measurements of plasma Z-AAT levels, Z-AAT protein accumulation in the liver, and expression of genes previously implicated in liver injury and development of fibrosis were taken. In addition, histological evaluations of globules and inflammation and an ultrastructural evaluation of the liver by electron microscopy were performed.
Key results include the following:
-
Sustained RNAi reduction of Z-AAT substantially reversed the AATD
disease phenotype:
- Deeply reduced monomeric Z-AAT protein in the liver
- Reduced polymeric Z-AAT in the liver
- Prevented the dramatic increase in globule size seen in age-matched control PiZ mice
- Improved abnormal endoplasmic reticulum morphology
- Prevented inflammation
- Prevented/reduced expression of fibrosis, redox-regulation, stress, apoptosis and autophagosome-associated genes
- Resulted in abundance of healthy mitochondria
Poster Presentation Details:
Reduction of hepatic Z-alpha1 antitrypsin by RNA interference (RNAi) prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse
- Presentation Reference: FRI-446
- Session: Poster: Rare liver diseases (including pediatric and genetic)
-
Session Date and Time:
April 12, 2019 at9:00 a.m. to 5:00 p.m. CET -
Authors:
Christine Wooddell , et al.
Additional details, including the presentation abstract, can be found on the ILC website at https://ilc-congress.eu/. A copy of presentation materials can be accessed by visiting the Events section under the Investors tab of the Arrowhead website.
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20190412005066/en/
Source:
Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince
Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com